Asensus Surgical, Inc.

Asensus Surgical Announces Purchase of Senhance Robotic System by RZD Medicine

Retrieved on: 
Monday, November 29, 2021
Technology, Surgery, Medical Devices, FDA, Hospitals, Other Health, Health, Pharmaceutical, Data Management, Patient, Private Securities Litigation Reform Act, Security (finance), General surgery, CEO, Sale, Movement, Bed, Securities Act of 1933, Time, Deep learning, Annual report, Surgery, Hospital, NYSE, Surgeon, Health, Private Healthcare Information Network, SEC, Gynaecology, U.S. Securities and Exchange Commission, Program, Goal, Securities Exchange Act of 1934, Medicine, Machine learning, ISU, Thought, Neurosurgery, Robot-assisted surgery, Department, Intelligence, Dentistry, Medical device, RZD Medicine, Asensus Surgical, Inc., RZD MEDICINE, ASENSUS SURGICAL, INC.

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today announced Private Healthcare Institution Railway Clinical Hospital RZD Medicine of Rostov-on-Don (RZD Medicine), located in Rostov, Russia, has initiated its Senhance Robotic Surgery program following the purchase of a Senhance Surgical System.

Key Points: 
  • Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today announced Private Healthcare Institution Railway Clinical Hospital RZD Medicine of Rostov-on-Don (RZD Medicine), located in Rostov, Russia, has initiated its Senhance Robotic Surgery program following the purchase of a Senhance Surgical System.
  • RZD Medicine is home to a high volume, multidisciplinary general surgery department that can leverage Senhance across a wide variety of procedures, said Anthony Fernando, Asensus Surgical President and CEO.
  • Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.
  • This press release includes statements relating to the Senhance Surgical System and RZD Medicine initiating a program with the Senhance System.

Asensus Surgical Announces Franklin Medical Center to Initiate the Installation of the Senhance Surgical System

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Surgery, Medical Devices, Health, Pharmaceutical, Securities Exchange Act of 1934, Intelligence, Adoption, Robotics, Private Securities Litigation Reform Act, Health, Movement, Security (finance), Baystate Health, CEO, Machine learning, Goal, ISU, General surgery, Securities Act of 1933, Program, Annual report, Deep learning, Surgery, Sale, Hospital, U.S. Securities and Exchange Commission, Surgeon, SEC, NYSE, Patient, Dentistry, 3D printing, Medical device, Franklin Medical Center, Asensus Surgical, Inc., FRANKLIN MEDICAL CENTER, ASENSUS SURGICAL, INC.

Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.

Key Points: 
  • Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.
  • The Senhance Surgical System is powered by the Intelligent Surgical Unit (ISU).
  • Franklin Medical Center is an acute-care hospital in Winnsboro, Louisiana serving Franklin, Tensas, and Catahoula Parishes in Louisiana.
  • This press release includes statements relating to the Senhance Surgical System and Franklin Medical Center initiating a program with the Senhance System.

Asensus Surgical Announces Shinmatsudo Central General Hospital in Japan to Initiate Senhance Robotic Surgical System

Retrieved on: 
Monday, November 1, 2021
Hospitals, Health, Surgery, Medical Devices, Securities Act of 1933, Hospital, Goal, Surgery, Surgeon, Deep learning, Â, IMS, Health, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Security (finance), Machine learning, NYSE, SEC, Intelligence, Annual report, CEO, Movement, Program, ISU, Securities Exchange Act of 1934, Sale, Physician, Dentistry, Medical device, Shinmatsudo Central General Hospital, Asensus Surgical, Inc., SHINMATSUDO CENTRAL GENERAL HOSPITAL, ASENSUS SURGICAL, INC.

We are excited to partner with the Shinmatsudo Central General Hospital, which has extensive experience as a center for excellence in both laparoscopic and surgical robotics, said Anthony Fernando, Asensus Surgical President, and CEO.

Key Points: 
  • We are excited to partner with the Shinmatsudo Central General Hospital, which has extensive experience as a center for excellence in both laparoscopic and surgical robotics, said Anthony Fernando, Asensus Surgical President, and CEO.
  • Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.
  • We are looking forward to incorporating Senhance into our existing surgical robotics department, said Dr. Ryota Matsuo,M.D.,Ph.D., the director of the Shinmatsudo Central General Hospital.
  • This press release includes statements relating to the Senhance Surgical System and Shinmatsudo Central General Hospital initiating a program with the Senhance System.

Asensus Surgical, Inc. Announces Hirosaki University Hospital to Initiate Senhance Robotic Surgery Program

Retrieved on: 
Wednesday, October 6, 2021
Technology, Surgery, Medical Devices, FDA, Biotechnology, Health, Pharmaceutical, General Health, Data Management, Da Vinci Surgical System, Adoption, Goal, ISU, Securities Act of 1933, Hope, Deep learning, Health, Digital, Annual report, Security (finance), Sale, Private Securities Litigation Reform Act, Image, U.S. Securities and Exchange Commission, Surgeon, Patient, Surgery, Professor, CEO, Program, 3D, Intelligence, Securities Exchange Act of 1934, Machine learning, Movement, NYSE, Pediatric surgery, SEC, Department, Dentistry, Hirosaki University Hospital, Asensus Surgical, Inc., HIROSAKI UNIVERSITY HOSPITAL, ASENSUS SURGICAL, INC.

We are excited to add a system at Hirosaki University Hospital to help build out its Senhance Robotic Surgery Program, said Anthony Fernando, Asensus Surgical President and CEO.

Key Points: 
  • We are excited to add a system at Hirosaki University Hospital to help build out its Senhance Robotic Surgery Program, said Anthony Fernando, Asensus Surgical President and CEO.
  • Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.
  • The initiation of the Senhance program contributes to our emphasis on the delivery of innovative medicine, said Dr. Kenichi Hakamada, Professor and Chairman, Department of Gastroenterological Surgery Department of Pediatric Surgery.
  • This press release includes statements relating to the Senhance Surgical System and Hirosaki University Hospital initiating a program with the Senhance System.

Asensus Surgical, Inc. Announces Sapporo Medical University Hospital in Japan to Initiate Senhance Robotic Surgery Program

Retrieved on: 
Wednesday, September 29, 2021
Data Management, Health, FDA, Medical Devices, Technology, Surgery, Pharmaceutical, Adoption, Goal, ISU, Securities Act of 1933, Regenerative medicine, Deep learning, Health, Disaster, Annual report, Drug Quality and Security Act, Surgical oncology, Private Securities Litigation Reform Act, Security (finance), Sale, U.S. Securities and Exchange Commission, Surgeon, Patient, Surgery, Sapporo, CEO, Program, AIDS, Intelligence, Securities Exchange Act of 1934, Machine learning, Robotics, Movement, Bed, HIV, NYSE, SEC, Dentistry, Medicine, Medical device, Sapporo Medical University Hospital, Asensus Surgical, Inc., SAPPORO MEDICAL UNIVERSITY HOSPITAL, ASENSUS SURGICAL, INC.

Sapporo Medical University Hospital has facilities in 29 clinical divisions and 932 inpatient beds.

Key Points: 
  • Sapporo Medical University Hospital has facilities in 29 clinical divisions and 932 inpatient beds.
  • In 1996, the hospital was certified as an advanced treatment facility capable of providing advanced medical treatment, developing medical technologies, and offering training.
  • The hospital also functions as an AIDS treatment core hospital (HIV Hokkaido Regional Hospital), a core disaster medical hospital, the Hokkaido Rehabilitation Support Center, and a regional cancer center.
  • This press release includes statements relating to the Senhance Surgical System and Sapporo Medical University Hospital initiating a program with the Senhance System.

Asensus Surgical Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center

Retrieved on: 
Monday, September 27, 2021
Technology, Surgery, Medical Devices, FDA, Other Technology, Software, Health, Pharmaceutical, Data Management, Goal, Robot-assisted surgery, ISU, Securities Act of 1933, Hope, Deep learning, Health, Digital, Annual report, Security (finance), Sale, Private Securities Litigation Reform Act, Image, U.S. Securities and Exchange Commission, Surgeon, Patient, Surgery, MCSC, Russian National Research Medical University, CEO, Program, 3D, Intelligence, Securities Exchange Act of 1934, Research, Machine learning, Movement, NYSE, Loginov, SEC, Department, Dentistry, Loginov Moscow Clinical Scientific Center, Asensus Surgical, Inc., LOGINOV MOSCOW CLINICAL SCIENTIFIC CENTER, ASENSUS SURGICAL, INC.

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today announced that Loginov Moscow Clinical Scientific Center, located in Moscow, Russia, has initiated its Senhance Robotic Surgery program following the purchase of a Senhance Surgical System.

Key Points: 
  • Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today announced that Loginov Moscow Clinical Scientific Center, located in Moscow, Russia, has initiated its Senhance Robotic Surgery program following the purchase of a Senhance Surgical System.
  • The Senhance Surgical System is powered by the Intelligent Surgical Unit (ISU).
  • The Loginov Moscow Clinical Scientific Center (The Loginov MCSC) is one of the largest and most innovative institutions funded by the Moscow Health Department.
  • This press release includes statements relating to the Senhance Surgical System and The Loginov Moscow Clinical Scientific Center hospital initiating a program with the Senhance System.

Asensus Surgical to Join the Russell 2000® and Russell Microcap® Indexes

Retrieved on: 
Tuesday, June 8, 2021
Biotechnology, Health, Surgery, Medical devices, Russell Indexes, Stock market indices, Index fund, FTSE Russell, Russell 2000 Index, Finance, Index, Investment management, Money, Russell 2500 Index, Russell Small Cap Completeness Index, Asensus Surgical, Inc., FTSE Russell, ASENSUS SURGICAL, INC., FTSE RUSSELL

FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Key Points: 
  • FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
  • We're thrilled to be a part of the Russell 2000 Index and believe that our inclusion will increase our visibility and exposure to investors, said Anthony Fernando, President and CEO of Asensus Surgical.
  • Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
  • For more information on the Russell 2000 Index and the Russell indexes reconstitution, go to the Russell Reconstitution section on the FTSE Russell website .

Asensus Surgical Announces LAKUMED Hospitals in Germany to Initiate Senhance Program

Retrieved on: 
Monday, May 10, 2021
Hospitals, Health, Surgery, Medical devices, Clinical medicine, Medicine, Digestive system surgery, Endoscopy, Laparoscopy, Surgery, Asensus Surgical, Inc., LAKUMED Hospitals, ASENSUS SURGICAL, INC., LAKUMED HOSPITALS

The system will be utilized at the Landshut-Achdorf hospital which is located in the Landshut region, just outside of Munich, Germany.\n\xe2\x80\x9cWe are very pleased that LAKUMED hospitals have chosen to utilize a Senhance Surgical System,\xe2\x80\x9d said Anthony Fernando, Asensus Surgical President and CEO.

Key Points: 
  • The system will be utilized at the Landshut-Achdorf hospital which is located in the Landshut region, just outside of Munich, Germany.\n\xe2\x80\x9cWe are very pleased that LAKUMED hospitals have chosen to utilize a Senhance Surgical System,\xe2\x80\x9d said Anthony Fernando, Asensus Surgical President and CEO.
  • \xe2\x80\x9cGermany is the largest surgical market in Europe, and has grown into the largest European country for Senhance in terms of users, surgeries and hospitals.
  • This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit\xe2\x84\xa2 (ISU\xe2\x84\xa2) to increase surgeon control and reduce surgical variability.
  • To learn more visit: https://www.lakumed.de/lang/english/about-lakumed/\nThis press release includes statements relating to the Senhance Surgical System and Landshut-Achdorf hospital initiating a program with the Senhance System.